View all the latest information in graft-versus-host disease, arranged by trials and clinical studies. Listed below are recently added trial updates.
BMT CTN 1202 biorepository study report on acute GvHD diagnosis and adjudication
The accuracy of acute graft-versus-host disease (GvHD) diagnosis is critical for the evaluation of new treatments and...
TCT Meeting 2019 | A report from the BMT CTN 1202 biorepository trial: Acute graft-versus-host disease diagnosis and adjudication
Ran Reshef presented the findings of the BMT CTN 1202 biorepository...
T-cell costimulation blockade with abatacept for acute GvHD: Results of the ABA2 trial
There are still no approved agents for preventing severe acute (a) graft-versus-host disease (GvHD), which is a...
TCT Meeting 2019 | Results of the phase II ABA2 trial: abatacept for acute GvHD prophylaxis in unrelated donor transplantation
These findings indicate that short-course (four doses) of abatacept is...
FDA accepts a supplemental new drug application for ruxolitinib in steroid-refractory cGvHD
On February 22, 2021, the U.S. Food and Drug Administration (FDA) granted priority review to a supplemental...
ASH 2020 | Practice-changing abstracts in graft-versus-host disease
Did you miss ASH 2020? The GvHD Hub attended the 62nd ASH Annual Meeting & Exposition, December 5-8 2020, and has developed a...
The ROCKstar study (KD025-213): What patients with chronic GvHD benefit most from belumosudil?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to...
ROCKstar: Belumosudil in chronic GvHD – an update from ASH 2020
Inhibition of the Rho-associated coiled-coil kinase 2 (ROCK2) has been shown to inhibit STAT3 signaling, thereby downregulating...
BMT CTN 1101
BMT CTN 1202
BMT CTN 1203
BMT CTN 1501